Edition:
United States

Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

154.07USD
23 May 2017
Change (% chg)

$1.05 (+0.69%)
Prev Close
$153.02
Open
$152.65
Day's High
$154.57
Day's Low
$152.16
Volume
3,581,999
Avg. Vol
3,623,681
52-wk High
$184.21
52-wk Low
$133.64

Select another date:

Tue, May 9 2017

BRIEF-Feldan Therapeutics and Elasmogen announce research agreement with Amgen

* Feldan Therapeutics and Elasmogen announce research agreement with Amgen to develop intracellular biologics

BRIEF-Amgen files for potential five-part senior notes offering

* Amgen inc files for potential five-part senior notes offering - sec filing Source text for Eikon: (http://bit.ly/2qh9EEe) Further company coverage:

BRIEF-Amgen, Harvard Pilgrim agree to contract for repatha

* Amgen and Harvard Pilgrim agree to first cardiovascular outcomes-based refund contract for repatha (evolocumab)

UPDATE 1-India watchdog orders antitrust probe into Roche cancer drug

MUMBAI, April 27 India's antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients.

Cost controls help offset lower Amgen first-quarter drug sales

Amgen Inc on Wednesday reported higher-than-expected first-quarter profit as cost controls helped offset a sharp drop in sales of Enbrel, its blockbuster rheumatoid arthritis and psoriasis drug.

BRIEF-Amgen reports Q1 GAAP earnings per share $2.79

* Says 2017 earnings per share guidance increased to $10.64-$11.32 on GAAP basis, and $12.00-$12.60 on non-GAAP basis

UPDATE 3-Cost controls help offset lower Amgen 1st-quarter drug sales

April 26 Amgen Inc on Wednesday reported higher-than-expected first-quarter profit as cost controls helped offset a sharp drop in sales of Enbrel, its blockbuster rheumatoid arthritis and psoriasis drug.

BRIEF-Amgen optimistic for Enbrel sales rebound

* Amgen says optimistic about rebound in Enbrel sales in coming quarters after Q1 decline

Amgen first-quarter profit exceeds Street estimates on lower costs

April 26 Amgen Inc on Wednesday reported higher-than-expected first-quarter profit as cost controls helped offset a sharp drop in sales of Enbrel, its blockbuster rheumatoid arthritis and psoriasis drug.

BRIEF-Coherus Biosciences completes formalities with amgen for Coherus' CHS-1701

* Completed initial phases of biologics price competition & innovation act patent exchange procedure with amgen for Coherus' CHS-1701

Select another date:

More From Around the Web